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Introduction: Acquired tamoxifen resistance remains the major obstacle to breast cancer endocrine therapy.
β1-integrin was identified as one of the target genes of G protein-coupled estrogen receptor (GPER), a novel
estrogen receptor recognized as an initiator of tamoxifen resistance. Here, we investigated the role of β1-integrin
in GPER-mediated tamoxifen resistance in breast cancer.
Methods: The expression of β1-integrin and biomarkers of epithelial-mesenchymal transition were evaluated
immunohistochemically in 53 specimens of metastases and paired primary tumors. The function of β1-integrin
was investigated in tamoxifen-resistant (MCF-7R) subclones, derived from parental MCF-7 cells, and MCF-7R
β1-integrin-silenced subclones in MTT and Transwell assays. Involved signaling pathways were identified
using specific inhibitors and Western blotting analysis.
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Results: GPER, β1-integrin and mesenchymal biomarkers (vimentin and fibronectin) expression in metastases
increased compared to the corresponding primary tumors; a close expression pattern of β1-integrin and GPER were
in metastases. Increased β1-integrin expression was also confirmed in MCF-7R cells compared with MCF-7 cells. This
upregulation of β1-integrin was induced by agonists of GPER and blocked by both antagonist and knockdown of it
in MCF-7R cells. Moreover, the epidermal growth factor receptor/extracellular regulated protein kinase (EGFR/ERK)
signaling pathway was involved in this transcriptional regulation since specific inhibitors of these kinases also reduced
the GPER-induced upregulation of β1-integrin. Interestingly, silencing of β1-integrin partially rescued the sensitivity of
MCF-7R cells to tamoxifen and the α5β1-integrin subunit is probably responsible for this phenomenon. Importantly,
the cell migration and epithelial-mesenchymal transition induced by cancer-associated fibroblasts, or the product of
cancer-associated fibroblasts, fibronectin, were reduced by knockdown of β1-integrin in MCF-7R cells. In addition, the
downstream kinases of β1-integrin including focal adhesion kinase, Src and AKT were activated in MCF-7R cells and
may be involved in the interaction between cancer cells and cancer-associated fibroblasts.
Conclusions: GPER/EGFR/ERK signaling upregulates β1-integrin expression and activates downstream kinases, which
contributes to cancer-associated fibroblast-induced cell migration and epithelial-mesenchymal transition, in MCF-7R
cells. GPER probably contributes to tamoxifen resistance via interaction with the tumor microenvironment in a
β1-integrin-dependent pattern. Thus, β1-integrin may be a potential target to improve anti-hormone therapy responses
in breast cancer patients.Introduction
Tamoxifen, a selective estrogen receptor (ER) modulator,
is the most frequently used anti-hormonal drug for the
adjuvant treatment of women with ER-positive breast
cancer [1]. Acquired resistance is still the major clinical
challenge to the therapeutic efficacy of tamoxifen. A
growing amount of evidence has demonstrated that the
aberrant activated growth factor signaling pathways con-
tribute to tamoxifen resistance [2, 3]. However, most
studies [4, 5] have tested the hypothesis that tamoxifen
resistance results from genetic alterations and autocrine
or paracrine mechanisms in the epithelial tumor cells
themselves. Tumors are complex organs comprising a
variety of components such as tumor cells, fibroblasts,
immune cells, vessels, and extracellular matrix. The role
of the tumor microenvironment in tumor progression
and drug resistance is gradually being clarified [6, 7].
One of the crucial reasons for drug resistance is the
metastasis of cancer cells to secondary sites [8, 9].
Tumor cells achieve this by activating an epithelial-
mesenchymal transition (EMT) program to experience
phenotypic alterations, such as the loss of cell-cell inter-
actions and the gain of cell mobility to evade from the
primary lesion. Molecular hallmarks of EMT include the
loss of epithelial markers, such as E-cadherin, the
gain of the expression of mesenchymal markers, such
as N-cadherin, vimentin and fibronectin, the loss of
cell polarity, and reorganization of the actin cytoskel-
eton accompanied by the morphological change [10, 11].
For example, tamoxifen-resistant MCF-7 breast cancer
cells (MCF-7R) display enhanced motile and invasive be-
havior as well as accompanying EMT-like properties com-
pared to the parental MCF-7 cell line in vitro [12, 13].Emerging evidence suggests a close association between
drug resistance and the induction of EMT in cancer
[10, 14]; however, the initiator and the specific mech-
anism of EMT during the development of tamoxifen
resistance remain to be determined.
G protein-coupled estrogen receptor (GPER), also
called G protein-coupled receptor 30 (GPR30), is a novel
ER that can be activated by tamoxifen and the pure anti-
estrogen fulvestrant. This receptor has been shown to be
important in the induction of tamoxifen resistance
through the GPER/epidermal growth factor receptor
(EGFR) signaling pathway [15, 16]. Moreover, it was
demonstrated GPER functions as an important initiator
in the development of tamoxifen resistance in hormone-
dependent breast cancer [17]. In order to further
disclose the potential role of GPER in the tamoxifen-
resistant ER+ breast cancer, we identified a set of target
genes in MCF-7R subclones using cDNA microarray
(data unpublished). One of these genes, β1-integrin, has
been demonstrated to play a key role in tumor progres-
sion and tumor survival [18, 19]. Furthermore, β1-
integrin, which coordinates much broader functional
processes such as inflammation, proliferation, adhesion,
and invasion, has recently been implicated in therapeutic
resistance in multiple solid cancer models [20, 21]. Im-
portantly, integrins mediate signal transduction between
the tumor cell and its microenvironment, which compli-
cates the identification of the mechanisms underlying
drug resistance. Few studies have reported the involve-
ment of β1-integrin in tamoxifen resistance. Pontiggia
and colleagues [22] demonstrated that soluble factors
or extracellular matrix components in the microenvir-
onment protect against tamoxifen-induced cell death
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sensitive breast cancer cells. However, this finding
does not clarify the role of β1-integrin in resistant cells due
to the diversity of the cell model.
In this study, we elucidated that the interaction of the
cancer-associated fibroblast (CAF)-derived tumor micro-
environment and β1-integrin locating on the cell
membrane of MCF-7R cells plays a key role in GPER-
mediated tamoxifen resistance. Increased β1-integrin
was detected in metastasis (MT) breast carcinoma speci-
mens compared with their matched primary tumors
(PTs). Knockdown of β1-integrin expression in MCF-7R
cells partly restored tamoxifen sensitivity and suppressed
the EMT phenotype facilitated by CAFs, or the product
of CAFs, fibronectin, in vitro. These findings suggest
that targeting β1-integrin may be a promising solution
to tamoxifen resistance in breast cancer.
Methods
Materials
The rabbit monoclonal (EP1041Y) antibody against β1-
integrin was obtained from Abcam (Cambridge, UK).
Antibodies against Src (pY418 and total), focal adhesion
kinase (FAK; pY397 and total), extracellular-signal regu-
lated kinase-1 and -2 (ERK1/2; pT202/Y204), E-cadherin,
vimentin and fibronectin were purchased from Bioworld
(Saint Louis Park, MN, USA). Antibodies against AKT
(pS473 and total) were from Cell Signaling Technology
(New England Biolabs, Herts, UK). β1-integrin antisense
oligonucleotides and GAPDH antisense oligonucleo-
tides were purchase from Invitrogen (New York,
USA). Fibronectin, 4-hydroxytamoxifen (TAM) and
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were obtained from Sigma-Aldrich (Steinheim,
Germany). GPER agonist G1 and antagonist G15 were
purchased from Tocris (Missouri, USA). Function-
blocking integrin monoclonal antibodies specific for
α2β1-integrins (AK-7) and α5β1 integrin (P1D6) were
from EMD Biosciences (San Diego, CA, USA). All other
reagents were from Beyotime (Haimen, China).
Cell culture
Human MCF-7 breast carcinoma cells (MCF-7), pur-
chased from the Institute of Biochemistry and Cell
Biology, Chinese Academy of Sciences (IBCB, Shanghai,
China), were routinely grown in Dulbecco's modified
Eagle's medium (DMEM; Gibco, Rockville, MD, USA) con-
taining 5% fetal bovine serum (FBS; Gibco), 10 μg/ml insu-
lin, 100 IU/ml penicillin and 100 μg/ml streptomycin. The
tamoxifen-resistant sublines (MCF-7R) [23] were derived
from MCF-7 by continuous exposure to TAM diluted in
0.1% ethanol. MCF-7R cells were cultured continuously in
medium containing 5% FBS supplemented with 100 nM
TAM. Before all experiments, cells were switched tophenol-free DMEM containing 0.5% charcoal-dextran-
stripped FBS for 2 days, except where noted.
MDA-MB-468, MDA-MB-231, and SKBR3 cells were
kindly provided by Dr Gang Tu, and the culture condi-
tions were as described previously [24].
CAFs, a gift from Dr Manran Liu, were isolated and
cultured as described previously [25].
No consent was needed from any patients or Institute
Ethics Board, because only commercially available cell
lines were used in this study.
Specimens
The 77 paired archival paraffin-embedded breast cancer
specimens were obtained from the Clinical Diagnostic
Pathology Center, Chongqing Medical University
(Chongqing, China). All patient details and exclusion
criteria have been described previously [17]. All patients
received tamoxifen only after surgery. All patients in-
volved in this study consented to participate in the study
and publication of its results. The experiments were ap-
proved by the Ethics Committee of the First Affiliated
Hospital of Chongqing Medical University and were con-
ducted in accordance with the Helsinki Declaration.
Immunohistochemistry
Sections of formalin-fixed and paraffin-embedded breast
cancer specimens or corresponding recurrent lesions
were mounted on SuperFrost Plus glass slides (ZsBio,
Beijing, China) and dried overnight. The immunohisto-
chemical protocols are described elsewhere [17]. The
slides were incubated with affinity-purified rabbit anti-
β1-integrin (1:100), anti-GPER (1:250), anti-E-cadherin
(1:200), anti-vimentin (1:200) and anti-fibronectin (1:200)
for 2 hours at 37 °C.
Evaluation of β1-integrin and G protein-coupled estrogen
receptor staining
The β1-integrin expression in samples was scored based
on intensity (0 to 3) and extent (0 = <10%, 1 = 10 to
25%, 2 = 26 to 50%, 3 = >50%) ato ccording previously
described criteria [26]. The individual categories were
multiplied to give a total immunohistochemical score
ranging between 0 and 9. Samples that scored ≥3 were
defined as positive immunohistochemical results.
GPER expression was classified as described previously
[17] and scores were assigned as follows: the percentage
of positive cells was categorized as 0 (negative staining
in all cells), 1 (<1% cells stained), 2 (1 to 10% of cells
stained), 3 (11 to 40% cells stained), 4 (41 to 70% cells
stained) or 5 (71 to 100% cells stained), and staining
intensity was categorized as 0 (negative), 1 (weak), 2
(moderate) or 3 (strong). Percentage and intensity
scores were added to give total immunohistochemical
scores, ranging from 0 to 8. Specimens that scored ≥2 were
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breast cancer specimens were identified as GPER-positive
and the rest were GPER-negative in a total of 77 recurrent
samples.
Evaluation of epithelial-mesenchymal transition marker
protein expression
Expression of EMT marker proteins (E-cadherin, vimen-
tin, fibronectin) were also detected immunohistochemi-
cally in PTs of breast cancer and paired MTs. Expression
of membranous E-cadherin, cytoplasmic vimentin and
fibronectin was scored using the following system [27]:
0 (no staining); 1 (1 to 25% staining); 2 (26 to 50%
staining); 3 (>50% staining).
Construction of GV115-sh/β1-integrin and siRNA
transfection
Four short hairpin RNA (shRNA) sequences targeting
the β1-integrin gene and one negative control sequence
were designed, and inserted into the lentivirus vector
GV115 containing a green fluorescent protein (GFP)
reporter. Recombinant lentivirus and control were ex-
tracted after transfection of 293 T cells with the recom-
binant vector and helper vectors. The lentivirus with the
best interfering effect as determined by real-time PCR
was selected to infect MCF-7R cells. The selected β1-
integrin shRNA vector sequence (No. 1756–1) was as
follows: forward, 5′-CCGGGAGGAAATGGTGTTTG
CAAGTTTCAAGAGAACTTGCAAACACCATTTCCT
CTTTTTG-3′; and reverse, 3′-CTCCTTTACCACAA
ACGTTCAAAGTTCT CTTGAACGTTTGTGGTAAA
GGAGAAAAACTTAA-5′. Reagents and technical sup-
port were from GeneChem (Shanghai, China). The other
β1-integrin shRNA vector sequences and negative con-
trol vector sequence are listed in Additional file 1:
Table S1. The MCF-7R subclones expressing downreg-
ulated β1-integrin were established through infecting
the MCF-7R cells with β1-integrin shRNA lentivirus.
The same method was used to transduce the negative
control virus into cells to control for the impact of the
lentivirus vector with the same methods. After infec-
tion for 8 hours, the culture medium was refreshed.
The cells were transfected with lentivirus vectors for
72 hours and used in subsequent studies. A second
shRNA (No. 1755–1) was utilized for data (Additional
file 2: Figure S1).
GPER-specific small interfering RNA (siRNA) and the
control siRNA sequence (gifts from Dr Gang Tu) were
transiently transferred into MCF-7R or SKBR3 cells. The
target sequences for GPER siRNA were 5′-GCUGUA
CAUUGAGCAGAAATT-3′ (A) and 5′-UUUCUG CUC
AAUGUACAGCTT-3′ (B). The control siRNA sequence
that did not match any known human cDNA was 5′-AAG
GTGTCAGAAACTGACGAT-3′. Expression of GPERprotein levels was analyzed by Western blotting after
transfection.
Measurement of cell growth
Cells were seeded in 96-well plates at 5 × 103 cells/well.
After 24 hours, the cells were treated with different con-
centrations of TAM for the time indicated, and the
medium was renewed on day 3. The vehicle (0.1%
ethanol) was used as a control. At the end of the treat-
ment, 20 μl 5 mg/ml MTT was added into the medium
and incubated for 4 hours at 37°C. After removing
medium, 150 μl MTT solvent (DMSO) was added to
each well for 15 minutes and optical density (OD) values
were read in a digital spectrophotometer (λ = 490 nm).
Each experiment was repeated three times. All the OD
values, divided by the average of their controls, were
converted to a percentage of the control.
Wound healing assay and Transwell assays
For wound healing assays, MCF-7R cells were infected
with lentivirus vectors targeting β1-integrin or negative
control. GFP expression in breast cancer cells at least 2
days after infection was observed by immunofluores-
cence microscopy. For co-culture preparation, 1 × 105
CAFs were grown to confluence in six-well dishes in
complete DMEM for 3 days. Breast cancer cells growing
in log-phase were digested with trypsin, and 2 × 105 cells
were plated onto the confluent CAFs. At 90% confluence, a
pipette tip was used to make a single scratch in the mono-
layer. Floating cells and debris were removed and cells were
incubated with minimum serum medium (DMEM + 0.5%
FBS + 100 IU/ml penicillin and 100 mg/ml streptomycin)
for 24 hours to allow cell growth and wound closure.
Images of the wound were obtained before and after the
24-hour period, then measured using Image J software
(National Institutes of Health, Bethesda, MD, USA).
For transwell assays, 2 × 104 breast cancer cells, sus-
pended in 200 μl serum-free medium, were seeded into
the upper well of a Boyden chamber with 8-μm pore size
filters (Millipore, Darmstadt, Germany). CAFs at ap-
proximately 80% confluence were washed and cultured
in fresh serum-free DMEM medium for 48 hours. The
medium was then collected and filtered for use mixed at
a 9:1 ratio with fresh DMEM with 10% FBS as condi-
tioned medium (CM). Normal medium (1% FBS) or CM
was added into the lower chamber with or without add-
ing TAM (1 μM) into the upper chamber according to
the experimental design. After incubation for 24 hours,
cells adhering to the upper surface of the filter were re-
moved using a cotton applicator. After staining with
0.5% crystal violet, the cells that had migrated to the
opposite side of the filter were counted. The data rep-
resent at least three experiments performed in triplicate
(mean ± standard error).
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Total RNA was extracted from MCF-7 and MCF-7R
cells using RNAiso reagent (TaKaRa, Dalian, China) ac-
cording to the manufacturer’s protocol. Total cDNA was
synthesized from RNA via a PrimeScript RT reagent Kit
(TaKaRa). The expression of β1-integrin was quantified
by quantitative real-time PCR performed with the Bio-
Rad Miniopticom Real-time PCR system using SYBR®
Premix EX Taq™II Kit (TaKaRa). The following primer
sequences were used: 5′-CCTACTTCTGCACGATGT
GATG-3′ (β1-integrin forward), 5′-CCTTTGCTACGG
TTGGTTACATT-3′ (β1-integrin reverse), 5′-TGACTT
CAACAGCGACACCCA-3′ (GAPDH forward) and 5′-
CACCCTGTTGCTGTAGCCAAA-3′ (GAPDH reverse).
All the samples were amplified by real-time PCR twice
and expression was normalized to GAPDH.
Western blotting
Cells were treated as described in the figure legends for
various times indicated in the results. Protein cell lysates
and Western blotting procedures were performed as
described previously [17]. Subcellular protein frac-
tions were extracted using a Cell Membrane Protein
Extraction Kit (Beyotime) following the manufacturer’s
instructions. Cellular proteins (50 μg) were boiled in
SDS-PAGE sample loading buffer and separated by 10%
SDS-PAGE, and the specific primary antibody which was
targeting each protein was incubated with the mem-
branes at 4°C overnight. Later, the membranes were
incubated with appropriate horseradish peroxidase-
conjugated secondary antibody and visualized using the
chemical luminescence imaging system. OD was analyzed
using Image J Software, and results normalized to β-actin
were expressed as fold change relative to the control.
Each experiment was performed at least three times with
representative gels shown.
Immunofluorescence
Cells were grown on sterile glass coverslips in 24-well
plates treated as described in the figure legends.
After 24 hours, cells were washed with cold PBS,
fixed in 4% paraformaldehyde, permeabilized with
0.2% Triton X-100, and blocked with 5% goat serum.
Cells were then incubated with the primary antibody
overnight at 4°C, and then with secondary antibody
conjugated with FITC or TRITC (1:200; ZsBio). DAPI
(Invitrogen) was used to visualize nuclei. The images
were viewed using a Nikon Eclipse 80i microscope
(Nikon, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using SPSS standard ver-
sion 19.0 software (Chicago, USA). Results are expressed
as means ± standard deviation from at least threeindependent determinations. The Student’s t-test was used
for single comparisons between two groups, and analysis
of variance followed by the Student–Newman–Keuls mul-
tiple comparisons test was used for comparison between
multiple groups. Values of P < 0.05 were considered statis-
tically significant.
Results
Consistency in changes in G protein-coupled estrogen
receptor, β1-integrin and epithelial-mesenchymal transition
marker protein expression in tumors that recurred during
treatment with tamoxifen
A total of 77 breast cancer tissues were eligible for ana-
lysis according to our previous inclusion criteria [17]; of
these, 53 recurrent breast cancer specimens (33 local
and 20 distant metastases) were identified as GPER+.
Among the 53 GPER+ specimens, GPER expression was
increased in 73.58% (39/53), decreased in 5.66% (3/53)
and unchanged in 20.76% (11/53) compared with the
matched PTs. All these GPER+ MTs and the paired PTs
were also used to determine β1-integrin expression. β1-
integrin was shown to be expressed predominantly on
the plasma membrane and GPER in the cell cytoplasm
(Fig. 1a).
Our previous report showed that the mean immuno-
histochemical score for GPER in MTs (6.23 ± 0.91)
was significantly increased compared with that in
PTs (3.46 ± 1.07; P = 0.001). To investigate the po-
tential relationship among GPER, β1-integrin and
tamoxifen resistance, β1-integrin expression was scored
in PTs and the paired MTs. β1-integrin expression was
increased in 79.2% (42/53), decreased in 5.66% (3/53) and
unchanged in 15.1% (8/53) of these 53 GPER+ tumors
that relapsed during tamoxifen treatment (Fig. 1b).
The mean immunohistochemical score for β1-integrin
was 4.60 ± 1.96 in PTs and 7.42 ± 1.69 in MTs (Fig. 1c,
P = 0.001). Among the 53 MTs (GPER+), β1-integrin
expression was positively correlated with GPER ex-
pression (Fig. 1d, R2 = 0.5330, P = 0.000).
To determine if the epithelial characteristics of breast
cancer cells exhibited transitions during clinical treat-
ment with tamoxifen, the expression of EMT marker
proteins (E-cadherin, vimentin and fibronectin) was
investigated in these 53 GPER+ MTs and paired PTs.
Representative weak staining and strong staining are
shown in Fig. 1a. Significant increases in cytoplasmic
vimentin (P = 0.001) and fibronectin (P = 0.011) ex-
pression scores were observed (mean immunohisto-
chemical scores: vimentin, 0.66 ± 0.586 in PTs and
1.38 ± 0.790 in MTs; fibronectin, 0.60 ± 0.631 in PTs
and 1.30 ± 0.822 in MTs). However, the mean immu-
nohistochemical score for E-cadherin in this group of
patients was 2.40 ± 0.716 in PTs and 2.25 ± 0.875 in
the recurrent lesions (P = 0.059).
Fig. 1 Immunohistochemical staining of β1-integrin, G protein-coupled estrogen receptor (GPER) and epithelial-mesenchymal transition (EMT)
marker proteins in breast cancer tissues. The predominant staining pattern of GPER, vimentin and fibronectin was cytoplasmic in carcinoma tissues,
whereas β1-integrin and E-cadherin were expressed mainly on the plasma membrane (A). (a-d) β1-integrin immunostaining showing representative
negative (a), weak (b), moderate (c) or strong positive plasma membrane staining (d). (e-h) GPER staining showing representative negative (e),
weak (f), moderate (g) or strong positive staining (h). (i-n) EMT marker proteins staining showing representative weak staining ((i) E-cadherin (k)
vimentin (m) fibronectin) and strong staining ((j) E-cadherin (l) vimentin (n) fibronectin). (o,p) Example of weak β1-integrin staining in primary
tumor (PT) (o) and strong β1-integrin expression in the corresponding metastasis (MT) (p) under tamoxifen treatment. Original magnification ×400.
Matched change (B) and quantitative (C) comparison of β1-integrin expression in PTs and their corresponding MTs. The correlation of β1-integrin and
GPER expression in MTs revealed through pair-wise scatter plots (D)
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β1-integrin expression in tamoxifen-resistant breast
cancer cells
It has been reported that GPER plays an important role
in tamoxifen resistance in breast cancer [15, 17]. To
explore the underlying mechanisms, we previously
screened the target genes of GPER via microarray ana-
lysis in breast cancer cells, and sixty target genes were
identified according to a rigorous screening criteria (data
unpublished; Additional file 3: Table S2). One of these
genes, β1-integrin, has been implicated in therapeutic
resistance in multiple solid cancer models [20, 21]. To
determine the role of β1-integrin in tamoxifen resist-
ance of breast cancer cells, we first evaluated its ex-
pression in tamoxifen-sensitive MCF-7 cells (MCF-7)
and tamoxifen-resistant MCF-7 cells (MCF-7R). The
increased β1-integrin expression in MCF-7R cells
compared to that in MCF-7 cells was confirmed by
quantitative RT-PCR, immunofluorescence and Western
blotting analyses (Fig. 2). Moreover, the β1-integrin protein
was upregulated by the GPER agonist G1 and TAM,
while the GPER-specific antagonist G15 and GPER-
specific siRNA abolished the agonistic action of TAM
in MCF-7R cells (Fig. 2d,e), indicating that β1-
integrin expression induced by TAM is mediated by
GPER. Interestingly, we saw a similar finding in an-
other GPER-positive cell line SKBR3 (Additional file 2:
Figure S2). It should be noted that G15 and GPER-
specific siRNA alone had no significant impact on β1-
integrin expression (data not shown).
The EGFR/ERK signaling pathway is directly responsible
for increased β1-integrin expression in MCF-7R cells
EGFR is involved in the induction of tamoxifen resist-
ance and is known to activate the MAPK/ERK and
PI3K/AKT pathways in breast cancer cells [28, 29]. It
was found that EGFR was highly expressed in MCF-7R
cells compared with MCF-7 cells (Fig. 3a). Moreover, it
has been previously demonstrated that TAM activates
the MAPK/ERK and PI3K/AKT pathways through the
GPER/EGFR signaling pathway in MCF-7R cells [15, 17].
To investigate whether these pathways are implicated in
inducing β1-integrin expression, MCF-7R cells were
treated with TAM alone or with the addition of the sig-
naling pathway inhibitors. The specific EGFR inhibitor
AG1478 (6 μM; Sigma-Aldrich) and the MAPK/ERK in-
hibitor U0126 (10 μM; Beyotime) abolished the agonistic
effect of TAM (1 μM) on the expression of β1-integrin,
while the PI3K inhibitor Wortmannin (1 μM; Sigma-
Aldrich) did not (Fig. 3b,c). None of the inhibitors had
any effect on β1-integrin expression when used alone
(data not shown). Our results suggest that TAM stimu-
lates β1-integrin expression in MCF-7R cells via the
GPER/EGFR/ERK signaling pathway.Blockage of β1-integrin partially rescues the sensitivity of
MCF-7R cells to tamoxifen
The effects of β1-integrin silencing in MCF-7R cells
were investigated to determine the role of β1-integrin in
tolerance to TAM. The expression of β1-integrin protein
was silenced with a lentivirus-mediated shRNA vector
(Fig. 4a). MCF-7R subclones with silenced β1-integrin
(MCF-7R-sh/ITGB1) were also established. Cell growth
following treatment with TAM (0 to 100 μM) for 108
hours was determined using MTT assays. As expected,
low TAM concentrations (0 to 1 μM) inhibited MCF-7
cell growth and stimulated MCF-7R cell growth. When
the concentration of TAM was elevated to 100 μM,
there was no obvious difference in cell survival, suggest-
ing off-target effects of TAM at high concentrations.
Excitingly, inhibition of β1-integrin expression in
MCF-7R restored the TAM inhibitory effect (Fig. 4b).
Additionally, investigation of the effect of therapeutic
concentrations of TAM (1 μM) on cell growth over
time showed that the inhibitory effects of TAM were
first apparent at 72 hours and were more significant
at 108 hours (Fig. 4c,d). Taken together, these obser-
vations demonstrate that β1-integrin plays an import-
ant role in acquired tamoxifen resistance.
In some instances, GPER enhances α5β1-integrin-
mediated fibronectin matrix assembly [30] that promotes
cellular adhesion, haptotaxis, and survival. Therefore, we
examined whether α5β1-integrin was involved in tam-
oxifen sensitivity. Pretreatment of MCF-7R cells with the
function-blocking antibody specific for α5β1-integrin
(P1D6), but not α2β1-integrin (AK-7), partially rescued
the sensitivity of MCF-7R cells to tamoxifen (Fig. 4e).
The effect of cancer-associated fibroblasts on cancer cell
migration is abolished by inhibition of β1-integrin
It has been reported that breast cancer cells display en-
hanced mobility following the acquisition of tamoxifen re-
sistance [12, 13]. The effects of β1-integrin inhibition on
cell migration were investigated using in vitro Transwell
assays. Unexpectedly, inhibition of β1-integrin expression
in MCF-7R cells had no significant effect on cell migration
regardless of the presence or absence of TAM (Fig. 5a).
Integrins function as a critical link between tumor cells
and the surrounding microenvironment [31]; therefore, we
investigated whether CAFs promoted breast cancer cell
migration and investigated the effects of β1-integrin inhib-
ition on this process. Interestingly, CAF-CM significantly
increased the Transwell migration of MCF-7R cells com-
pared with MCF-7 cells. Furthermore, the function of CM
was notably reversed by β1-integrin silence and the α5β1-
integrin-inhibitory antibody P1D6 (Fig. 5a,b). Additionally,
CM enhanced the cell migration of MDA-MB-231 cells,
but not MDA-MB-468 cells, through β1-integrin signaling
(Additional file 2: Figure S3).
Fig. 2 Tamoxifen-induced β1-integrin expression is mediated by G protein-coupled estrogen receptor in MCF-7R cells. MCF-7 cells and MCF-7R
cells were analyzed for the presence of β1-integrin by (a) RT-PCR, (b) Western blotting and (c) immunofluorescence. The relative fold-change was
compared with MCF-7 cells (*P < 0.05, Student’s t-test). (d) β1-integrin was detected through Western blotting. MCF-7R cells were treated with
ethanol (control), G1 (10 nM) and TAM (1 μM) alone or in combination with the G protein-coupled estrogen receptor (GPER) antagonist G15 (1 μM) for
24 hours. (e) Western blotting analysis was used to test the effect of GPER-specific siRNA on GPER (left panel) and β1-integrin (right panel) levels in
MCF-7R cells. Each experiment was repeated at least three times. Results are shown as fold-changes in optical density compared with the control, and
normalized to β-actin. *P < 0.05. Ctrl, control; ITGB1, β1-integrin; TAM, 4-hydroxytamoxifen
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Fig. 3 Tamoxifen induces β1-integrin expression through a mechanism that involves the EGFR and MAPK/ERK signaling pathways. (a) Levels of
EGFR were detected by Western blotting using specific antibodies in cells. MCF-7R cells were treated with ethanol (control), TAM (1 μM) alone or
with the addition of the specific signaling pathway inhibitor targeting to EGFR (AG1478; 6 μM; AG), MAPK/ERK (U0126; 10 μM) or PI3K (Wortmannin;
10 μM; WM). β1-integrin expression was detected by (b) Western blotting and (c) immunofluorescence analyses. Each experiment was repeated at least
three times. Western blotting results are shown as fold-changes in optical density compared with the control, and normalized to β-actin. *P < 0.05. Ctrl,
control; ITGB1, β1-integrin; TAM, 4-hydroxytamoxifen
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Fig. 4 β1-integrin silencing restores the tamoxifen sensitivity in MCF-7R cells. (a) The effect of a lentivirus-mediated short hairpin RNA (shRNA)
vector targeting β1-integrin was measured by Western blotting in MCF-7R cells. Results are shown as fold-changes in optical density compared
with the control (sh/Vec), and normalized to β-actin. *P < 0.05, versus control. Cells were treated with (b) the indicated concentrations of TAM for
108 hours or (c) with therapeutic concentrations of TAM (1 μM) for the indicated time. The data represent means ± standard deviation from three
different experiments (aP < 0.05, MCF-7R cells versus MCF-7 cells; bP < 0.05, MCF-7R-sh/Vec versus MCF-7R-sh/ITGB1). (d) Cells were treated with
1 μM TAM and counted after 108 hours. (e) Cell numbers were measured in MCF-7R cells that were left untreated (UN) or pretreated with the
specific inhibitory antibody for α2β1-integrin (AK-7; 20 μg/ml) or α5β1-integrin (P1D6; 10 μg/ml) before TAM stimulation. Results are expressed as
means ± standard deviation of three independent experiments. *P < 0.05, versus each control. ITGB1, β1-integrin; MCF-7R-sh/ITGB1, MCF-7R
cells infected with lentivirus vector targeting β1-integrin; MCF-7R-sh/Vec, MCF-7R cells infected with negative control lentivirus (control);
TAM, 4-hydroxytamoxifen
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on the tumor cell migration, a wound healing assay
was performed under direct co-culture conditions.
The size of the scratched area narrowed and almost
closed within 24 hours when breast cancer cells were
co-cultured with CAFs, observed by phase-contrast
microscopy. However, fluorescent photomicrographsshowed that the breast cancer cells expressing GFP
migrated into the scratched area. Our study found
that, although CAFs nearly closed the wound area in
the two groups, the MCF-7R cells with silenced β1-
integrin (MCF-7R-sh/ITGB1) showed relatively weak
migratory capacity compared with the control group
(MCF-7R-sh/Vec) (Fig. 5c).
Fig. 5 β1-integrin mediates the effect of cancer-associated fibroblasts on breast cancer cell migration. Cell migratory capacity was assessed in
Transwell assays and wound healing assay. (a) In vitro Transwell assays were performed using cancer-associated fibroblast (CAF)-conditioned
medium (CM) or normal medium with or without the addition of TAM (1 μM). (b) The number of cells with indicated pretreatment that migrated
toward the lower wells of the transwell containing CM was counted. Each experiment was repeated at least three times. *P < 0.05. (c) The
capacity of cells to migrate to fill a scratched area devoid of cells was assessed in co-cultures of breast cancer cells and CAFs. Before co-culture,
breast cancer cells were infected with lentivirus carrying a green fluorescent protein reporter gene to distinguish CAFs under a fluorescence
microscope. Fluorescence photomicrographs revealed that MCF-7R-sh/Vec showed enhanced cell migration ability into the scratched area (arrows) when
compared with MCF-7R-sh/ITGB1. Ctrl, control; ITGB1, β1-integrin; MCF-7R-sh/ITGB1, MCF-7R cells infected with lentivirus vector targeting β1-integrin;
MCF-7R-sh/Vec, MCF-7R cells infected with negative control lentivirus (control); TAM, 4-hydroxytamoxifen
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activated on acquisition of tamoxifen resistance
The MCF-7R cell line was developed through long-term
exposure to TAM. Immunoblot analysis of the MCF-7R
revealed obvious elevation of phosphorylated (p)AKT
and ERK in MCF-7R compared with untreated parentalMCF-7 cells (Fig. 6a). In MCF-7R cells, the levels of the
β1-integrin downstream kinases pFAK (Y397) and pSrc
(Y418) were also increased significantly (Fig. 6a). Fur-
thermore, cells were treated with 1 μM TAM for 24
hours, and FAK and Src activity was then determined by
Western blotting. TAM promoted phosphorylation of
Fig. 6 (See legend on next page.)
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Fig. 6 Tamoxifen induces the activation of FAK, Src and AKT through β1-integrin in MCF-7R cells. (a) Cells were treated with or without TAM
(1 μM) for 24 hours prior to the analysis of protein expression by Western blotting. (b) The effects of TAM (1 μM for 24 hours) on pFAK and pSrc
were investigated by Western blotting in MCF-7R with silenced β1-integrin (sh/ITGB1) and control cells (sh/Vec). (c) MCF-7R cells were cultured
with TAM (1 μM) for the indicated time, then AKT and ERK1/2 activity was measured by Western blotting using specific antibodies. (d) MCF-7R
cells with silenced β1-integrin (sh/ITGB1) and control cells (sh/Vec) were treated with TAM (1 μM) for 10 minutes and then analyzed by Western
blotting. Each experiment was repeated at least three times. Results are shown as fold-changes in optical density compared with total levels, and
normalized to β-actin. *P < 0.05. Ctrl, control; ITGB1, β1-integrin; sh/ITGB1, MCF-7R cells infected with a lentivirus vector targeting β1-integrin;
sh/Vec, MCF-7R cells infected with negative control lentivirus; TAM, 4-hydroxytamoxifen
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in MCF-7 cells, while total FAK and Src were unaffected
(Fig. 6a), which was consistent with CM treatment (data
not shown).
The levels of pFAK and pSrc were decreased modestly
and no changes in total levels were detected in β1-
integrin-downregulated MCF-7R cells. Additionally, the
positive effect of TAM on FAK and Src activity was sup-
pressed by β1-integrin inhibition (Fig. 6b).
Activation of the AKT signaling pathway in response to
TAM is mediated by β1-integrin in tamoxifen-resistant
MCF-7 cells
Activation of AKT and MAPK is known to play a pivotal
role in tamoxifen resistance. Also, ERK1/2, part of a
major MAPK pathway cascade, mediates mitogenesis in
hormone-sensitive breast cancer cells. We tested the ef-
fect of TAM on phosphorylation of AKT and ERK in
MCF-7R cells and compared this to control cells. Al-
though there was no marked alteration in AKT and
EKR1/2 activity at 24 hours after TAM treatment
(Fig. 6a), TAM mediated their rapid phosphorylation
with peak increases at 10 minutes in MCF-7R cells
(Fig. 6c). However, the activation of AKT and EKR1/2 was
much later and weaker in MCF-7 cells (data not shown).
Moreover, our data showed that activation of the AKT
signaling pathway in response to TAM is mediated by β1-
integrin in MCF-7R cells (Fig. 6d). Interestingly, Huang
and colleagues found similar results in lapatinib-resistant
HER2+/ER+ and Her2+/ER− cell lines [21].
β1-integrin is involved in the cancer-associated
fibroblast-induced epithelial-mesenchymal transition
process in MCF-7R cells
Acquired chemotherapeutic resistance is accompanied
by an aggressive, invasive phenotype as a result of EMT
[8, 9]. In the current study, Western blotting analysis
showed increased expression of vimentin and fibronectin
in MCF-7R cells compared with that in MCF-7 cells.
However, there was no significant difference in the level
of E-cadherin expression (Fig. 7a). These results were
confirmed by immunofluorescence staining. Interest-
ingly, although E-cadherin expression was not decreased
in association with tamoxifen resistance, it was found tobe translocated from the cell membrane to the cyto-
plasm (Fig. 7b,c). Our data suggest that MCF-7R cells
display EMT-like properties compared to MCF-7 cells
in vitro.
The microenvironment of cancer cells, which contains
several distinct stromal cell types, participates in both
tumor progression and the response to treatment
[32, 33]. CAFs, which are one of the most crucial
components of the tumor microenvironment, possess
biological properties and functions that are distinct
from those of normal fibroblasts [34]. It has been re-
ported that CAFs promote cancer cell growth and migra-
tion through an involvement in angiogenesis and EMT
[35, 36]. To determine whether CAFs have the capacity
to regulate tumor progression, MCF-7 cells and MCF-7R
cells were cultured in the CM. The expression of fibro-
nectin and vimentin was significantly elevated in MCF-
7R cells cultured in CM compared to those cultured in
normal medium. However, CM exerted a marginal effect
on MCF-7 cells (Fig. 7d). Moreover, the assumptive
E-cadherin decrease was not observed in breast can-
cer cells cultured in CM. To determine if β1-integrin
modulates the CAF-induced EMT process, we tested
the effect of CM on MCF-7R cells with silenced β1-
integrin (MCF-7R-sh/ITGB1). The influence of CM
on the induction of EMT in MCF-7R was found to
be neutralized by β1-integrin inhibition (Fig. 7e). Fur-
thermore, PI3K inhibitor Wortmannin reversed the
stimulatory effect of CM (Fig. 7e,f ). To identify the
underlying EMT-inducing factor in CM, we investi-
gated whether the extracellular matrix (ECM) com-
ponent fibronectin, the main ligand of α5β1-integrin,
was involved in the process. Interestingly, fibronectin
had a similar impact on EMT induction in MCF-7R cells
(Additional file 2: Figure S4).
Discussion
The ability to overcome endocrine resistance is one of
the important aims for hormone-dependent breast can-
cer patients [37]. GPER, a novel membrane-bound estro-
gen receptor, has been demonstrated to contribute to
the development of tamoxifen resistance [15, 17]. How-
ever, the specific mechanism is less clearly elucidated. In
the present study, we found that tamoxifen resistance
Fig. 7 (See legend on next page.)
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Fig. 7 β1-integrin is implicated in the epithelial-mesenchymal transition process induced by cancer-associated fibroblasts in MCF-7R cells.
(a) Equal amounts of total cell protein were separated by SDS-PAGE and subsequently probed with antibodies against E-cadherin, fibronectin and
vimentin. (b) Localization and expression of E-cadherin and vimentin (red) in MCF-7, MCF-7R, and cancer-associated fibroblast (CAF) cell
lines were revealed by immunofluorescence staining. The nucleus was stained blue with DAPI. Original magnification: ×200. (c) Levels
of membrane E-cadherin were detected by Western blotting using specific antibodies. Na+/K+-ATPase was used for normalization. (d) Cells
were cultured in CAF-conditioned medium (CM) or normal medium for 48 hours, and the expression of E-cadherin, fibronectin and vimentin
was then determined by Western blotting. (e) β1-integrin expression in MCF-7R cells was blocked by lentivirus vector transfection (left panel).
Cells were left untreated (control; Ctrl) or treated with CM for 48 hours, or pretreated with the PI3K inhibitor Wortmannin (10 μM; WM) or the
MAPK/ERK inhibitor U0126 (10 μM) prior to CM treatment, and then cell lysates were probed with antibodies against fibronectin and vimentin
(right panel). (f) Cell migration of MCF-7R cells with indicated pretreatments was measured through Transwell assays. Each experiment was repeated at
least three times. Western blotting results are shown as fold-changes in optical density compared with the control, and normalized to β-actin.
*P < 0.05. ITGB1, β1-integrin; sh/ITGB1, MCF-7R cells infected with a lentivirus vector targeting β1-integrin; sh/Vec, MCF-7R cells infected with
negative control lentivirus
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microenvironment/β1-integrin interaction and accom-
panied by EMT. More interestingly, tamoxifen-resistant
MCF-7 cells (MCF-7R) were shown to be more suscep-
tible to EMT than MCF-7 cells in the presence of
stromal CAFs, which are one of the predominant mem-
bers in the tumor microenvironment, in a β1-integrin-
dependent manner.
GPER, whose action differs from the classical nuclear
estrogen receptors (ERα, ERβ), acts as an independent
ER in breast cancer cells and has been implicated in me-
diating both rapid and transcriptional events in responseFig. 8 Illustration depicting the role of G protein-coupled estrogen recepto
induced by cancer-associated fibroblasts. Long-term exposure to tamoxifen
(GPER) to the cell membrane, which enhances the crosstalk between GPER
is responsible for the increase in cAMP generation in breast cancer cells an
(PKA) on Raf, whereas cAMP production triggered by GPER is disorganized
activation of ERK1/2. Tamoxifen, as an agonist for GPER, stimulates the indu
pathway. Upregulation of β1-integrin is accompanied by the activation of t
activity. Conditioned medium (CM) produced by cancer-associated fibrobla
activation of PI3K/AKT, with the involvement of β1-integrin. Targeted thera
tumor microenvironment on cell motility. ECM, extracellular matrix; ITGB1, βto estrogen under certain circumstances [16, 24, 38]. Al-
though no increased basal expression of GPER in MCF-
7R cells is observed when compared to MCF-7 cells,
translocation of GPER from the cytoplasm to cell mem-
brane reinforces the crosstalk between GPER and EGFR
during long-term treatment with tamoxifen in breast
cancer cells [15, 17]. This crosstalk is followed by phos-
phorylation of MAPK and AKT, which subsequently
stimulates gene transcription and development of tam-
oxifen resistance [15].
β1-integrin is an important member of a family of
heterodimeric transmembrane adhesion proteins [6].r and β1-integrin in the epithelial-mesenchymal transition process
promotes the translocation of G protein-coupled estrogen receptor
and epidermal growth factor receptor (EGFR). The Ga subunit of GPER
d cAMP attenuates ERK1/2 activity by suppressing protein kinase A
upon acquisition of tamoxifen resistance leading to the increased
ction of β1-integrin expression through the GPER/EGFR/ERK signaling
he β1-integrin signaling pathway, which is measured by FAK and Src
sts (CAFs) induces epithelial-mesenchymal transition (EMT) through the
py with β1-integrin could reverse the stimulatory effect of CAFs in the
1-integrin; MMP, matrix metalloproteinase
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that β1-integrin is involved in therapeutic resistance in
various tumor types [20, 21, 39, 40]. Indeed, β1-integrin
was identified as one of the GPER target genes in MCF-
7R cells in our previous work (unpublished data). Here,
we found that enhanced β1-integrin expression in MCF-
7R cells was mediated via GPER/EGFR/ERK signaling;
the significantly increased β1-integrin in metastases com-
pared with the matched PTs was closely GPER-related.
This was supported by a proteomic analysis of acquired
tamoxifen resistance in MCF-7 cells [41]. Additionally, as
downstream kinases of β1-integrin, Src and FAK kinase
activity was significantly enhanced and involved in cellu-
lar invasion and motility in tamoxifen-resistant breast
cancer cells [42, 43]. These findings suggest that GPER-
mediated tamoxifen resistance is associated with the
enhanced β1-integrin and its downstream signaling acti-
vation in breast cancer cells.
In this study, MCF-7R cells displayed EMT-like prop-
erties compared to MCF-7 cells in vitro and clinical
tamoxifen-resistant breast tumor tissues. Although no
significant total E-cadherin expression was detected, de-
creased membrane E-cadherin was detected in MCF-7R
cells. It has been shown that E-cadherin internalization
is a key step in its dysfunction [12, 44], indicating EMT
is responsible for the adverse phenotype in MCF-7R
cells. β1-integrin is known to be implicated in the malig-
nant tumor characteristics, such as increased migration
and invasion, in a variety of tumor types [18, 20, 45, 46].
Interestingly, we observed that a potential ability for the
development of EMT was acquired after MCF-7R cells
were exposed to CAFs, CAF-derived CM, or fibronectin
treatment. Indeed, some of elements in ECM, such as col-
lagen I, collagen III and collagen IV were reported to pro-
tect tumor cells from chemotherapy attraction [32, 47, 48].
ECM acts as a substrate to which cells adhere and serves
as a reservoir for growth factors [49]. The ECM compo-
nent fibronectin is the crucial ligand of α5β1-integrin [30,
31]; the cross-talk between fibronectin and β1-integrin
could activate a downstream signaling pathway network in
EMT transition (our unpublished data). Several previous
reports demonstrated that EMT characteristics might
confer a chemo-drug resistant potential in tumor cells
[10, 14]. In the current study, we further disclosed that
CAF-derived fibronenctin conferred EMT phenotype to
MCF-7R cells through the α5β1-integrin/PI3K/AKT sig-
naling axis. These data have highlighted the significance
of the tumor microenvironment in tamoxifen resistance
and tumor progression. Our findings support the notion
that therapy regimens abrogating the complex interac-
tions of the carcinomas with the tumor microenvir-
onment could be a future alternative to overcome
tamoxifen resistance in breast cancer, and β1-integrin
may be a promising target.Conclusions
In summary, our data provide a novel insight into un-
derstanding the role of the tumor microenvironment in
tamoxifen-resistant breast cancer. Long-term tamoxifen
treatment facilitates translocation of GPER to cell mem-
branes, resulting in aberrant activation of the EGFR/ERK
signaling pathway and upregulation of β1-integrin ex-
pression which is responsible for the enhanced com-
munications between tumor cells and the tumor
microenvironment (Fig. 8). Blockage of GPER/EGFR/
ERK/β1-integrin signaling may be a potential target
in enhancing their sensitivity for tamoxifen-resistant
breast cancer patients. However, it is undoubted that
further investigations, including in vivo experiments
and prospective clinical studies, are needed.Additional files
Additional file 1: Table S1. Sequences of shRNA vectors targeting
β1-integrin gene and one negative control.
Additional file 2: Figure S1. A second shRNA sequence applied to
MCF-7R cells confirms the important role of β1-integrin in tamoxifen
resistance of breast cancer. The effect of this shRNA on β1-integrin
expression (A), cell growth (B) and cell migration (C) was detected
with the same method as previously described. *P < 0.05. Figure S2. GPER
mediates the upregulation of β1-integrin induced by tamoxifen in SKBR3
cells. (A) The expression of GPER was knockdown by GPER-specific siRNA
transfection in SKBR3 cells. *P < 0.05, versus control. (B) Western blotting
analysis was used to test the effect of TAM on the level of β1-integrin
treated with or without GPER specific siRNA transfection in SKBR3 cells.
*P < 0.05. Figure S3. β1-integrin governs the effect of CAFs on
MDA-MB-231 cells migration. (A) β1-integrin expression was determined
in cells. (B) Expression of β1-integrin was silenced by lentivirus-mediated
shRNA in MDA-MB-231 cells. *P < 0.05, versus control. (C) In vitro Transwell
assays were performed using CAF-conditioned medium (CM) or normal
medium in MDA-MB-468, MDA-MB-231, MDA-MB-231 cells with silenced
β1-integrin (MDA-MB-231-sh/ITGB1) and control cells (MDA-MB-231-sh/Vec).
*P < 0.05. Figure S4. Fibronectin induces the EMT process through
α5β1-integrin and PI3K/AKT signaling in MCF-7R cells. MCF-7R cells
were treated with fibronectin (30 μg/ml; FN) for 48 hours, or pretreated
with or without α5β1-integrin inhibitory antibody P1D6 (10 μg/ml), the
PI3K inhibitor Wortmannin (10 μM; WM), and the MAPK/ERK inhibitor
U0126 (10 μM) prior to FN treatment, and then cell lysates were probed
with antibodies against fibronectin and vimentin. *P < 0.05.
Additional file 3: Table S2. List of 60 target genes of GPER. The target
genes were picked out through cDNA microarray analysis (unpublished
data) according to the rigorous screening criteria: at least two-fold
increase in MCF-7R cells compared with MCF-7 cells, at least 1.25-fold
induction by TAM, at least 1.5-fold induction by G1, and at least 50%
suppression of TAM effect by G15 in MCF-7R cells.Abbreviations
CAF: cancer-associated fibroblast; CM: conditioned medium; DMEM: Dulbecco's
modified Eagle's medium; ECM: extracellular matrix; EGFR: epidermal growth
factor receptor; EMT: epithelial-mesenchymal transition; ER: estrogen receptor;
FBS: fetal bovine serum; GFP: green fluorescent protein; GPER: G protein-coupled
estrogen receptor; MT: metastasis; OD: optical density; PT: primary tumor;
shRNA: short hairpin RNA; siRNA: small interfering RNA.Competing interests
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